PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced the appointment of Stephan Toutain, MS, MBA, as Chief Operating Officer (COO), effective as of May 1, 2024.

新泽西州普林斯顿，2024年5月2日（环球通讯社）--PDS生物技术公司（纳斯达克：PDSB）（“PDS生物技术”或“公司”）是一家晚期免疫治疗公司，专注于改变免疫系统如何靶向和杀死癌症以及传染病疫苗的开发，今天宣布任命MBA斯蒂芬·托坦为首席运营官（COO），自2024年5月1日起生效。

“We are thrilled to welcome Stephan to the PDS Biotech team as Chief Operating Officer. His invaluable experience spans many aspects of the life sciences industry, from drug development to commercialization, providing a wealth of knowledge to our team,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech.

PDS Biotech总裁兼首席执行官Frank Bedu Addo博士说：“我们很高兴欢迎Stephan作为首席运营官加入PDS Biotech团队。他的宝贵经验涵盖了生命科学行业的许多方面，从药物开发到商业化，为我们的团队提供了丰富的知识。”。

“Stephan’s strategic vision, proven ability to drive operational excellence, and distinguished track record, particularly in oncology, will be instrumental as we advance our lead program into a pivotal clinical trial.' Mr. Toutain brings more than 30 years of operational experience in the pharmaceutical industry from drug development, general management, operations, commercial development, market access and sales and marketing leadership with prior global expertise in the oncology and orphan drugs markets.

“Stephan的战略愿景、经证明的卓越运营能力以及杰出的业绩记录，尤其是在肿瘤学方面，将有助于我们将领先项目推进关键的临床试验。”Toutain先生在制药行业拥有30多年的运营经验，包括药物开发、综合管理、运营、商业开发、市场准入以及销售和营销领导，拥有肿瘤学和孤儿药市场的全球专业知识。

Before joining PDS Biotech, he served as COO at Anavex Life Sciences from May 2018 to April 2024 and Chief Commercial Officer at Interleukin Genetics from July 2016 to August 2017. Mr. Toutain also worked with Alnylam Pharmaceuticals to build its early access program. In addition, he led Global Commercial Development for Sarepta Therapeutics and served as General Manager for Alexion Pharmaceuticals in Europe.

在加入PDS Biotech之前，他于2018年5月至2024年4月担任Anavex Life Sciences的首席运营官，并于2016年7月至2017年8月担任白细胞介素遗传学的首席商务官。Toutain先生还与Alnylam Pharmaceuticals合作建立了早期获取计划。此外，他还领导了Sarepta Therapeutics的全球商业开发，并担任亚力兄制药（Alexion Pharmaceuticals）在欧洲的总经理。

Mr. Toutain has also held various U.S. commercial, marketing and product management positions with Celgene Corporation and Joh.

Toutain先生还曾在Celgene Corporation和Joh担任过多个美国商业、营销和产品管理职位。